You have 9 free searches left this month | for more free features.

MCL1

Showing 1 - 25 of 694

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Myopia Trial in Singapore (Myopia Control Lens-1 (MCL1), Myopia Control Lens-2 (MCL2))

Not yet recruiting
  • Myopia
  • Myopia Control Lens-1 (MCL1)
  • Myopia Control Lens-2 (MCL2)
  • Singapore, Singapore
    Essilor R&D Centre Singapore
Nov 27, 2023

Acute Myeloid Leukaemia Trial in Australia, France, United States (S 64315 (also referred as MIK665) and venetoclax)

Terminated
  • Acute Myeloid Leukaemia
  • S 64315 (also referred as MIK665) and venetoclax
  • New Haven, Connecticut
  • +6 more
Dec 20, 2022

Acute Myeloid Leukaemia Trial in Worldwide (S 64315 (also referred as MIK665) and azacitidine)

Active, not recruiting
  • Acute Myeloid Leukaemia
  • S 64315 (also referred as MIK665) and azacitidine
  • Houston, Texas
  • +6 more
Dec 16, 2022

Aggressive B-Cell Non-Hodgkin's Lymphoma, Aggressive B-Cell NHL, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial

Not yet recruiting
  • Aggressive B-Cell Non-Hodgkin's Lymphoma
  • +4 more
  • (no location specified)
Dec 16, 2022

Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma Trial in Worldwide (MIK665)

Completed
  • Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
  • Houston, Texas
  • +7 more
Jul 27, 2021

Mantle Cell Lymphoma (MCL) Trial in Australia, Canada, United States (Acalabrutinib, Venetoclax, Rituximab)

Not yet recruiting
  • Mantle Cell Lymphoma (MCL)
  • Duarte, California
  • +11 more
Jul 17, 2023

Mantle Cell Lymphoma, Refractory Lymphoma Trial in Boston (Acalabrutinib, Venetoclax, Obinutuzumab)

Recruiting
  • Mantle Cell Lymphoma
  • Refractory Lymphoma
  • Boston, Massachusetts
  • +1 more
Aug 8, 2022

Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive Trial in Houston (Acalabrutinib, Venetoclax)

Recruiting
  • Blastoid Variant Mantle Cell Lymphoma
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib, Ublituximab, Umbralisib)

Suspended
  • Mantle Cell Lymphoma
  • Duarte, California
    City of Hope Medical Center
Jun 7, 2022

Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS) Trial in Worldwide (S64315 once a week, S64315 twice a week)

Completed
  • Acute Myeloid Leukaemia (AML)
  • Myelodysplastic Syndrome (MDS)
  • S64315 once a week
  • S64315 twice a week
  • New Haven, Connecticut
  • +8 more
May 17, 2022

CLL, SLL, Richter's Transformation Trial in United States (TG-1801, Ublituximab)

Recruiting
  • CLL
  • +9 more
  • TG-1801
  • Ublituximab
  • Fayetteville, Arkansas
  • +4 more
Jan 20, 2023

Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type DLBCL (ABC-DLBCL), Mantle Cell Lymphoma (MCL) Trial in Indianapolis, Spokane

Recruiting
  • Non-Hodgkin's Lymphoma (NHL)
  • +4 more
  • Indianapolis, Indiana
  • +1 more
Jul 12, 2022

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Eprenetapopt, Venetoclax)

Withdrawn
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Feb 23, 2022

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL) Trial in Manchester,

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +7 more
  • Manchester, United Kingdom
  • +2 more
Aug 11, 2022

Chronic Lymphocytic Leukemia, Chronic Graft-versus-host-disease, Mantle Cell Lymphoma Trial in Poland (Acalabrutinib 2x100 MG

Recruiting
  • Chronic Lymphocytic Leukemia
  • +4 more
  • Acalabrutinib 2x100 MG Oral Capsule + alloSCT
  • Warszawa, Mazowieckie, Poland
  • +5 more
Dec 23, 2021

CLL/SLL, NHL, MCL Trial in United States (HMPL-760)

Recruiting
  • CLL/SLL
  • +8 more
  • Atlanta, Georgia
  • +3 more
Feb 24, 2022

Breast Cancer, HER2 Positive Trial in Netherlands (PTC+Pertuzumab, FEC-T+Pertuzumab)

Active, not recruiting
  • Breast Cancer
  • HER2 Positive
  • Alkmaar, Netherlands
  • +32 more
Oct 11, 2022

Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL) Trial in United States (voruciclib

Recruiting
  • Follicular Lymphoma (FL)
  • +6 more
  • voruciclib monotherapy
  • voruciclib and venetoclax
  • Duarte, California
  • +10 more
Aug 10, 2022

Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Tumor (SM-AHN), Mast Cell Leukemia (MCL) Trial in

Recruiting
  • Advanced Systemic Mastocytosis (AdvSM)
  • +3 more
  • CGT9486 tablets
  • Duarte, California
  • +10 more
Jul 8, 2022

MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,

Active, not recruiting
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +9 more
  • BTK inhibitor PCI-32765
  • +5 more
  • Columbus, Ohio
    Ohio State University Medical Center
Jun 27, 2022

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM) Trial in United States

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +6 more
  • Duarte, California
  • +10 more
Jul 14, 2022

Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome Trial in United States (PRT1419)

Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Orange City, Florida
  • +7 more
Oct 31, 2022

Acute Myeloid Leukemia Trial in Worldwide (Alvocidib, Cytarabine, Mitoxantrone)

Terminated
  • Acute Myeloid Leukemia
  • Scottsdale, Arizona
  • +37 more
Apr 4, 2022

Diffuse Large B-cell Lymphoma(DLBCL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL) Trial in Worldwide (AMG 562)

Completed
  • Diffuse Large B-cell Lymphoma(DLBCL)
  • +2 more
  • AMG 562
  • Duarte, California
  • +11 more
Feb 22, 2022

CCND1 Positive, CCND2 Positive, CCND3 Positive Trial in Houston (drug, other, biological)

Active, not recruiting
  • CCND1 Positive
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 11, 2022